A lmost 40% of the U.S. population older than 45 years has some degree of knee osteoarthritis (OA), and the estimated lifetime risk for knee OA is 14% (1) . This number is likely to rise even further. Obesity is skyrocketing, with an estimated 65 million more obese U.S. adults by 2030 (2) . Greater participation in sports has led to high rates of anterior cruciate ligament rupture, and up to half of persons with this injury will develop symptomatic knee OA (3) . Most important, the U.S. population is aging, with at least 92 million persons older than 65 years by 2060.
This increased prevalence of knee OA will lead to many persons living with chronic pain. To improve quality of life and minimize disability, these patients will need effective pain control. However, it is not necessarily clear which therapies work best for OA pain. One reason for therapeutic uncertainty is that more than half of OA pain studies and over 80% of those funded by the industry are less than 6 months in duration (4) . Osteoarthritis is a chronic disease, and results from short randomized, controlled trials may not necessarily reflect long-term responses. Another challenge is that most recommended treatment algorithms start with targeting elements of the peripheral nociceptive nervous system or decreasing inflammation. However, the peripheral nociceptive and inflammatory model is an incomplete explanation for chronic OA pain. Central sensitization, "an amplification of the neural signaling within the CNS [central nervous system] that elicits pain hypersensitivity," is clearly an important component of OA pain, which explains why medications, such as duloxetine, that work through centrally mediated analgesic mechanisms are effective treatments for knee OA (5) .
The complexity of chronic OA pain makes clinical research challenging because patients with knee OA are probably extremely diverse in their pain pathophysiology, despite a similar radiographic phenotype. This heterogeneity may also explain the discordance between results from well-executed randomized clinical trials, often with stringent inclusion criteria, and the choices patients make in the real world. For example, despite decades of research, the use of intra-articular hyaluronic acid remains extremely controversial. A recent meta-analysis and systematic review concluded that "in patients with knee osteoarthritis, viscosupplementation is associated with a small and clinically irrelevant benefit and an increased risk for serious adverse events" (6) . Disagreement is similar about glucosamine or chondroitin sulfate. The American Board of Internal Medicine and American Academy of Orthopedic Surgeons state as part of their Choosing Wisely campaign that glucosamine and chondroitin sulfate supplements do not work and are no better than placebo (7). Regardless, patients continue to demand these therapies. The global viscosupplementation market is estimated to be $2.5 billion by 2017, and the market for glucosamine is estimated to be $12 billion by 2020 (8, 9) .
Why this dichotomy? Perhaps despite our best efforts, patients with knee OA who enroll in randomized, controlled trials are simply not representative of realworld patients. Perhaps comparing interventions for OA pain with placebo-the gold standard for proving efficacy-fails to fully incorporate effects on centrally mediated pain, which may be similar between study groups. Or perhaps, as suggested in the study by Bannuru and colleagues (10) in this issue, all placebos are not created equal.
Bannuru and colleagues present results from a network meta-analysis that evaluates which treatments work best for knee OA. A network meta-analysis allows investigators to quantify the relative effectiveness of common treatments compared with each other and with placebo, which offers a good metric for establishing relative efficacy. This is a useful approachparticularly when large trials comparing multiple interventions will probably never be done-because it allows the comparison of results across many different studies, which increases the variety of patients contributing data. This network meta-analysis highlights some previously seen effects and also reveals some surprising findings. Acetaminophen, often recommended as a first-line treatment of knee OA, had the lowest effect size compared with oral placebo (0.18 [95% credible interval, 0.04 to 0.33]). Intra-articular hyaluronic acid had the highest effect size (0.63 [CrI, 0.39 to 0.88]), which was almost 1.5 times that of naproxen (0.38 [CrI, 0.27 to 0.49]). The authors hypothesize that the strong showing for injectable therapies may reflect an integrated intra-articular placebo effect; in fact, intraarticular placebo had an effect size of 0.29 (CrI, 0.04 to 0.54) compared with oral placebo. This effect of placebo delivery method cannot be identified in traditional meta-analyses and may be relevant to real-world clinical decision making.
An important limitation is that these efficacy estimates are calculated over a short time frame. The crucial question yet to be addressed is the durability of these treatments in individual patients. In addition, the principle of indirect comparisons is based on an assumption of consistency, which implies that all studies drew samples from the same underlying population and that samples were unbiased and representative. This is a difficult assumption to prove. A call for open access to data collected in randomized, controlled trials may help researchers conducting network metaanalyses to confirm such assumptions. It is also often the case that metrics used to delineate standardized differences do not necessarily have a clear clinical interpretation. It is important that data from network metaanalyses are presented in meaningful formats that are accessible to both patients and treating physicians.
With the dramatic rise in prevalence of knee OA, it will become increasingly important to create innovative research models to better understand how to optimize pain control and provide a road map for a rational approach to effective treatment. Research methods need to be designed with an understanding of the pathophysiology of OA pain, including both peripheral nociceptive and inflammatory triggers and central sensitization. A clear understanding of the role of placebo, pain pathophysiology, and patient preferences should be key factors facilitating shared decision making in treating patients with knee OA. Sophisticated analytic syntheses of existing evidence, such as that presented in the study by Bannuru and colleagues, will help ensure that patients receive the pain relief they deserve.
